{"id":56986,"date":"2026-02-12T21:35:41","date_gmt":"2026-02-12T13:35:41","guid":{"rendered":"https:\/\/flcube.com\/?p=56986"},"modified":"2026-02-12T21:35:42","modified_gmt":"2026-02-12T13:35:42","slug":"eli-lillys-jaypirca-wins-nmpa-approval-for-cll-sll-post-btk-inhibitor-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56986","title":{"rendered":"Eli Lilly\u2019s Jaypirca Wins NMPA Approval for CLL\/SLL Post-BTK Inhibitor Therapy"},"content":{"rendered":"\n

Eli Lilly and Company<\/strong> (NYSE:\u202fLLY<\/a><\/strong>) announced that the National Medical Products Administration (NMPA)<\/strong> has approved Jaypirca (pirtobrutinib)<\/strong> for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL)<\/strong> in adult patients who have received at least one prior systemic therapy, including a BTK inhibitor<\/strong>. The non-covalent (reversible) BTK inhibitor<\/strong>, first approved by the FDA in January\u202f2023<\/strong>, becomes the first therapy in China specifically indicated for CLL\/SLL after covalent BTK inhibitor progression<\/strong>, addressing resistance and intolerance<\/strong> to ibrutinib, acalabrutinib, zanubrutinib, and orelabrutinib<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Eli Lilly and Company (NYSE:\u202fLLY); commercialized in China by Innovent Biologics<\/strong><\/td><\/tr>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Asset<\/strong><\/td>Jaypirca (pirtobrutinib) \u2013 Non-covalent BTK inhibitor<\/td><\/tr>
New Indication<\/strong><\/td>CLL\/SLL (\u22651 prior therapy, including BTK inhibitor)<\/td><\/tr>
Prior China Approval<\/strong><\/td>Mantle cell lymphoma (MCL)<\/strong> \u2013 October\u202f2024 (\u22652 prior therapies, including BTK inhibitor)<\/td><\/tr>
US Approval<\/strong><\/td>January\u202f2023 (CLL\/SLL and MCL)<\/td><\/tr>
Mechanism<\/strong><\/td>Reversible BTK binding<\/strong> \u2013 re-establishes pathway inhibition after covalent BTK inhibitor failure<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Differentiation & Mechanism<\/h2>\n\n\n\n
Feature<\/th>Pirtobrutinib Approach<\/th>Covalent BTK Inhibitors (Ibrutinib, Acalabrutinib, Zanubrutinib, Orelabrutinib)<\/th><\/tr><\/thead>
Binding Mechanism<\/strong><\/td>Non-covalent, reversible<\/strong><\/td>Covalent, irreversible<\/td><\/tr>
Resistance Overcome<\/strong><\/td>Active against C481S BTK mutation<\/strong> \u2013 most common resistance mechanism<\/td>Inactivated by C481S mutation<\/td><\/tr>
Intolerance Management<\/strong><\/td>Different safety profile<\/strong> \u2013 reduced cardiovascular toxicity<\/td>Atrial fibrillation, bleeding, hypertension risks<\/td><\/tr>
Prior Therapy Requirement<\/strong><\/td>Specifically indicated post-covalent BTK inhibitor<\/strong><\/td>First-line and early-line use<\/td><\/tr>
Clinical Utility<\/strong><\/td>Extends BTK pathway benefits<\/strong> in refractory population<\/td>Foundation of CLL\/SLL therapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Strategic Positioning<\/h2>\n\n\n\n
Factor<\/th>Strategic Analysis<\/th><\/tr><\/thead>
China CLL\/SLL Burden<\/strong><\/td>~10,000-15,000 new cases annually<\/strong>; BTK inhibitors standard of care<\/strong>; resistance\/intolerance creates significant refractory population<\/strong><\/td><\/tr>
Unmet Need<\/strong><\/td>No approved therapies specifically for post-covalent BTK inhibitor CLL\/SLL<\/strong> in China; chemotherapy or PI3K inhibitors<\/strong> (idelalisib) suboptimal<\/td><\/tr>
Innovent Commercialization<\/strong><\/td>Lilly-Innovent partnership<\/strong> leverages Innovent’s oncology sales force<\/strong> and hospital relationships<\/strong>; Lilly retains development control<\/strong><\/td><\/tr>
Competitive Landscape<\/strong><\/td>Zanubrutinib (BeiGene)<\/strong> and orelabrutinib (InnoCare)<\/strong> dominate first-line covalent BTK<\/strong>; pirtobrutinib captures resistance\/intolerance niche<\/strong><\/td><\/tr>
Global Alignment<\/strong><\/td>NMPA approval harmonizes with FDA\/EMA<\/strong>; supports regulatory consistency<\/strong> for global development strategy<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Development & Commercial Outlook<\/h2>\n\n\n\n
Priority<\/th>Execution Plan<\/th>Timeline<\/th><\/tr><\/thead>
Launch<\/strong><\/td>Hospital oncology access; hematology specialist education<\/td>Q1-Q2\u202f2026<\/td><\/tr>
Reimbursement<\/strong><\/td>NRDL negotiation for CLL\/SLL indication; leverage MCL approval precedent<\/td>2026<\/td><\/tr>
Market Positioning<\/strong><\/td>“BTK inhibitor after BTK inhibitor”<\/strong> \u2013 unique positioning vs. competitors<\/td>Ongoing<\/td><\/tr>
Combination Studies<\/strong><\/td>Explore pirtobrutinib + venetoclax or anti-CD20 antibodies<\/td>2026+<\/td><\/tr>
Expansion<\/strong><\/td>Potential earlier-line use in combination; other B-cell malignancies<\/td>Investigational<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding Jaypirca commercial performance in China, NRDL reimbursement outcomes, and competitive dynamics with zanubrutinib and orelabrutinib in the post-covalent BTK inhibitor setting. Actual results may differ due to pricing pressure from national procurement programs, physician adoption of non-covalent mechanism, and competitive responses from BeiGene and InnoCare.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Eli Lilly and Company (NYSE:\u202fLLY) announced that the National Medical Products Administration (NMPA) has approved…<\/p>\n","protected":false},"author":1,"featured_media":56988,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,199,911,15,33],"class_list":["post-56986","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-eli-lilly","tag-nyse-lly","tag-product-approvals","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"\nEli Lilly\u2019s Jaypirca Wins NMPA Approval for CLL\/SLL Post-BTK Inhibitor Therapy - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly and Company (NYSE:\u202fLLY) announced that the National Medical Products Administration (NMPA) has approved Jaypirca (pirtobrutinib) for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) in adult patients who have received at least one prior systemic therapy, including a BTK inhibitor. The non-covalent (reversible) BTK inhibitor, first approved by the FDA in January\u202f2023, becomes the first therapy in China specifically indicated for CLL\/SLL after covalent BTK inhibitor progression, addressing resistance and intolerance to ibrutinib, acalabrutinib, zanubrutinib, and orelabrutinib.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56986\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly\u2019s Jaypirca Wins NMPA Approval for CLL\/SLL Post-BTK Inhibitor Therapy\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly and Company (NYSE:\u202fLLY) announced that the National Medical Products Administration (NMPA) has approved Jaypirca (pirtobrutinib) for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) in adult patients who have received at least one prior systemic therapy, including a BTK inhibitor. The non-covalent (reversible) BTK inhibitor, first approved by the FDA in January\u202f2023, becomes the first therapy in China specifically indicated for CLL\/SLL after covalent BTK inhibitor progression, addressing resistance and intolerance to ibrutinib, acalabrutinib, zanubrutinib, and orelabrutinib.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56986\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-12T13:35:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-12T13:35:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1203.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56986#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56986\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly\u2019s Jaypirca Wins NMPA Approval for CLL\\\/SLL Post-BTK Inhibitor Therapy\",\"datePublished\":\"2026-02-12T13:35:41+00:00\",\"dateModified\":\"2026-02-12T13:35:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56986\"},\"wordCount\":450,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56986#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1203.webp\",\"keywords\":[\"Cancer\",\"Eli Lilly\",\"NYSE: LLY\",\"Product approvals\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56986#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56986\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56986\",\"name\":\"Eli Lilly\u2019s Jaypirca Wins NMPA Approval for CLL\\\/SLL Post-BTK Inhibitor Therapy - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56986#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56986#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1203.webp\",\"datePublished\":\"2026-02-12T13:35:41+00:00\",\"dateModified\":\"2026-02-12T13:35:42+00:00\",\"description\":\"Eli Lilly and Company (NYSE:\u202fLLY) announced that the National Medical Products Administration (NMPA) has approved Jaypirca (pirtobrutinib) for chronic lymphocytic leukemia (CLL)\\\/small lymphocytic lymphoma (SLL) in adult patients who have received at least one prior systemic therapy, including a BTK inhibitor. The non-covalent (reversible) BTK inhibitor, first approved by the FDA in January\u202f2023, becomes the first therapy in China specifically indicated for CLL\\\/SLL after covalent BTK inhibitor progression, addressing resistance and intolerance to ibrutinib, acalabrutinib, zanubrutinib, and orelabrutinib.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56986#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56986\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56986#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1203.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1203.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eli Lilly\u2019s Jaypirca Wins NMPA Approval for CLL\\\/SLL Post-BTK Inhibitor Therapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56986#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly\u2019s Jaypirca Wins NMPA Approval for CLL\\\/SLL Post-BTK Inhibitor Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly\u2019s Jaypirca Wins NMPA Approval for CLL\/SLL Post-BTK Inhibitor Therapy - Insight, China's Pharmaceutical Industry","description":"Eli Lilly and Company (NYSE:\u202fLLY) announced that the National Medical Products Administration (NMPA) has approved Jaypirca (pirtobrutinib) for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) in adult patients who have received at least one prior systemic therapy, including a BTK inhibitor. The non-covalent (reversible) BTK inhibitor, first approved by the FDA in January\u202f2023, becomes the first therapy in China specifically indicated for CLL\/SLL after covalent BTK inhibitor progression, addressing resistance and intolerance to ibrutinib, acalabrutinib, zanubrutinib, and orelabrutinib.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56986","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly\u2019s Jaypirca Wins NMPA Approval for CLL\/SLL Post-BTK Inhibitor Therapy","og_description":"Eli Lilly and Company (NYSE:\u202fLLY) announced that the National Medical Products Administration (NMPA) has approved Jaypirca (pirtobrutinib) for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) in adult patients who have received at least one prior systemic therapy, including a BTK inhibitor. The non-covalent (reversible) BTK inhibitor, first approved by the FDA in January\u202f2023, becomes the first therapy in China specifically indicated for CLL\/SLL after covalent BTK inhibitor progression, addressing resistance and intolerance to ibrutinib, acalabrutinib, zanubrutinib, and orelabrutinib.","og_url":"https:\/\/flcube.com\/?p=56986","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-12T13:35:41+00:00","article_modified_time":"2026-02-12T13:35:42+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1203.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56986#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56986"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly\u2019s Jaypirca Wins NMPA Approval for CLL\/SLL Post-BTK Inhibitor Therapy","datePublished":"2026-02-12T13:35:41+00:00","dateModified":"2026-02-12T13:35:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56986"},"wordCount":450,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56986#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1203.webp","keywords":["Cancer","Eli Lilly","NYSE: LLY","Product approvals","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56986#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56986","url":"https:\/\/flcube.com\/?p=56986","name":"Eli Lilly\u2019s Jaypirca Wins NMPA Approval for CLL\/SLL Post-BTK Inhibitor Therapy - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56986#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56986#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1203.webp","datePublished":"2026-02-12T13:35:41+00:00","dateModified":"2026-02-12T13:35:42+00:00","description":"Eli Lilly and Company (NYSE:\u202fLLY) announced that the National Medical Products Administration (NMPA) has approved Jaypirca (pirtobrutinib) for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) in adult patients who have received at least one prior systemic therapy, including a BTK inhibitor. The non-covalent (reversible) BTK inhibitor, first approved by the FDA in January\u202f2023, becomes the first therapy in China specifically indicated for CLL\/SLL after covalent BTK inhibitor progression, addressing resistance and intolerance to ibrutinib, acalabrutinib, zanubrutinib, and orelabrutinib.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56986#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56986"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56986#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1203.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1203.webp","width":1080,"height":608,"caption":"Eli Lilly\u2019s Jaypirca Wins NMPA Approval for CLL\/SLL Post-BTK Inhibitor Therapy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56986#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly\u2019s Jaypirca Wins NMPA Approval for CLL\/SLL Post-BTK Inhibitor Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1203.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56986","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56986"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56986\/revisions"}],"predecessor-version":[{"id":56989,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56986\/revisions\/56989"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56988"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56986"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56986"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56986"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}